NO322314B1 - Farmasoytisk preparat, sett som omfatter flere beholdere, samt anvendelse av troglitazon, pioglitazon og/eller BRL-49653 ved fremstilling av et medikament. - Google Patents

Farmasoytisk preparat, sett som omfatter flere beholdere, samt anvendelse av troglitazon, pioglitazon og/eller BRL-49653 ved fremstilling av et medikament. Download PDF

Info

Publication number: NO322314B1
Authority: NO; Norway
Prior art keywords: treatment; arteriosclerosis; troglitazone; xanthoma; prophylaxis
Prior art date: 1996-07-15

Application number

NO19990166A

Other languages

English (en)

Norwegian (no)

Other versions

NO990166L (no

NO990166D0 (no

Inventor

Toshihiko Fujiwara

Toshio Sada

Yoshio Tsujita

Naoyuki Maeda

Original Assignee

Sankyo Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-07-15

Filing date

1999-01-14

Publication date

2006-09-11

1999-01-14 Application filed by Sankyo Co filed Critical Sankyo Co

1999-01-14 Publication of NO990166D0 publication Critical patent/NO990166D0/no

1999-03-15 Publication of NO990166L publication Critical patent/NO990166L/no

2006-09-11 Publication of NO322314B1 publication Critical patent/NO322314B1/no

Links

239000003814 drug Substances 0.000 title claims abstract description 35
HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 title claims description 33
GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 title claims description 25
229960001641 troglitazone Drugs 0.000 title claims description 25
GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 title claims description 25
239000000825 pharmaceutical preparation Substances 0.000 title claims description 16
229960005095 pioglitazone Drugs 0.000 title claims description 16
YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 title claims description 11
238000004519 manufacturing process Methods 0.000 title claims description 4
238000011282 treatment Methods 0.000 claims abstract description 42
208000011775 arteriosclerosis disease Diseases 0.000 claims abstract description 35
206010003210 Arteriosclerosis Diseases 0.000 claims abstract description 32
238000011321 prophylaxis Methods 0.000 claims abstract description 18
238000002360 preparation method Methods 0.000 claims abstract description 10
229940079593 drug Drugs 0.000 claims description 29
206010048215 Xanthomatosis Diseases 0.000 claims description 20
206010048214 Xanthoma Diseases 0.000 claims description 19
239000004480 active ingredient Substances 0.000 claims description 7
150000001875 compounds Chemical class 0.000 abstract description 8
-1 (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl Chemical group 0.000 abstract description 2
239000003795 chemical substances by application Substances 0.000 description 27
206010022489 Insulin Resistance Diseases 0.000 description 21
208000001072 type 2 diabetes mellitus Diseases 0.000 description 21
230000000694 effects Effects 0.000 description 15
239000004129 EU approved improving agent Substances 0.000 description 14
241001465754 Metazoa Species 0.000 description 8
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
201000001320 Atherosclerosis Diseases 0.000 description 7
239000002333 angiotensin II receptor antagonist Substances 0.000 description 7
230000002265 prevention Effects 0.000 description 7
239000000126 substance Substances 0.000 description 7
206010020772 Hypertension Diseases 0.000 description 6
206010012601 diabetes mellitus Diseases 0.000 description 6
230000002401 inhibitory effect Effects 0.000 description 6
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
239000005541 ACE inhibitor Substances 0.000 description 4
241000283973 Oryctolagus cuniculus Species 0.000 description 4
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
230000003902 lesion Effects 0.000 description 4
238000000034 method Methods 0.000 description 4
239000000203 mixture Substances 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
229940126317 angiotensin II receptor antagonist Drugs 0.000 description 3
201000005577 familial hyperlipidemia Diseases 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
230000036454 renin-angiotensin system Effects 0.000 description 3
UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
208000035150 Hypercholesterolemia Diseases 0.000 description 2
102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
239000002220 antihypertensive agent Substances 0.000 description 2
238000011888 autopsy Methods 0.000 description 2
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 2
229960000830 captopril Drugs 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
235000012000 cholesterol Nutrition 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
150000004677 hydrates Chemical class 0.000 description 2
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
230000003516 hyperlipidaemic effect Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
230000003449 preventive effect Effects 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
238000012360 testing method Methods 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
102000005862 Angiotensin II Human genes 0.000 description 1
229940123413 Angiotensin II antagonist Drugs 0.000 description 1
101800000733 Angiotensin-2 Proteins 0.000 description 1
206010008190 Cerebrovascular accident Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
241001494479 Pecora Species 0.000 description 1
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
235000021068 Western diet Nutrition 0.000 description 1
229950006323 angiotensin ii Drugs 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000003143 atherosclerotic effect Effects 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
230000004531 blood pressure lowering effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
206010008118 cerebral infarction Diseases 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
229940000425 combination drug Drugs 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
210000001145 finger joint Anatomy 0.000 description 1
238000009472 formulation Methods 0.000 description 1
229960004580 glibenclamide Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
239000008187 granular material Substances 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
150000002460 imidazoles Chemical class 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000005012 migration Effects 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
239000000843 powder Substances 0.000 description 1
229960002965 pravastatin Drugs 0.000 description 1
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
238000011160 research Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
238000009495 sugar coating Methods 0.000 description 1
230000001629 suppression Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000003826 tablet Substances 0.000 description 1
150000003548 thiazolidines Chemical class 0.000 description 1
230000003639 vasoconstrictive effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Materials For Medical Uses (AREA)

NO19990166A 1996-07-15 1999-01-14 Farmasoytisk preparat, sett som omfatter flere beholdere, samt anvendelse av troglitazon, pioglitazon og/eller BRL-49653 ved fremstilling av et medikament. NO322314B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP18436896		1996-07-15
PCT/JP1997/002407 WO1998002183A1 (fr)	1996-07-15	1997-07-11	Compositions medicinales

Publications (3)

Publication Number	Publication Date
NO990166D0 NO990166D0 (no)	1999-01-14
NO990166L NO990166L (no)	1999-03-15
NO322314B1 true NO322314B1 (no)	2006-09-11

Family

ID=16152008

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO19990166A NO322314B1 (no)	1996-07-15	1999-01-14	Farmasoytisk preparat, sett som omfatter flere beholdere, samt anvendelse av troglitazon, pioglitazon og/eller BRL-49653 ved fremstilling av et medikament.
NO20056021A NO334217B1 (no)	1996-07-15	2005-12-16	Anvendelse av CS-866 til fremstilling av et medikament for anvendelse ved profylakse eller behandling av arteriosklerose.

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO20056021A NO334217B1 (no)	1996-07-15	2005-12-16	Anvendelse av CS-866 til fremstilling av et medikament for anvendelse ved profylakse eller behandling av arteriosklerose.

Country Status (18)

Country	Link
US (1)	US6610682B2 (fr)
EP (2)	EP0930076B1 (fr)
KR (1)	KR100540618B1 (fr)
CN (2)	CN1221259C (fr)
AT (2)	ATE283704T1 (fr)
AU (1)	AU714618B2 (fr)
CA (1)	CA2261040C (fr)
CZ (2)	CZ300089B6 (fr)
DE (2)	DE69734405T2 (fr)
DK (2)	DK1175902T3 (fr)
ES (2)	ES2250283T3 (fr)
HU (2)	HU227399B1 (fr)
IL (2)	IL128059A (fr)
NO (2)	NO322314B1 (fr)
NZ (1)	NZ333723A (fr)
PT (1)	PT930076E (fr)
RU (2)	RU2220723C2 (fr)
WO (1)	WO1998002183A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7045519B2 (en)	1998-06-19	2006-05-16	Chiron Corporation	Inhibitors of glycogen synthase kinase 3
JP2003518493A (ja) *	1999-12-24	2003-06-10	スミスクラインビーチャムパブリックリミテッドカンパニー	新規治療方法
DE19962924A1 (de)	1999-12-24	2001-07-05	Bayer Ag	Substituierte Oxazolidinone und ihre Verwendung
MXPA02010090A (es) *	2000-04-12	2003-02-12	Novartis Ag	Combinacion de al menos dos compuestos seleccionados de los grupos de un antagonista del receptor at-1 o un inhibidor ace o un inhibidor de la hmg-co-a reductasa.
US20030045515A1 (en) *	2001-05-24	2003-03-06	Lise Binderup	Combination medicament for treatment of neoplastic diseases
DE10129725A1 (de) *	2001-06-20	2003-01-02	Bayer Ag	Kombinationstherapie substituierter Oxazolidinone
US20040219208A1 (en) *	2001-08-03	2004-11-04	Ryu Kawamura	Sustained-release medicines
DE10300111A1 (de)	2003-01-07	2004-07-15	Bayer Healthcare Ag	Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
CA2514921C (fr) *	2003-01-31	2013-04-30	Sankyo Company, Limited	Utilisation combinee d'olmesartan medoxomil et d'azelnidipine ou d'amlodipine pour le traitement de l'arteriosclerose et de l'hypertension
GB0322552D0 (en) *	2003-09-26	2003-10-29	Astrazeneca Uk Ltd	Therapeutic treatment
DE10355461A1 (de)	2003-11-27	2005-06-23	Bayer Healthcare Ag	Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
JP4880591B2 (ja) *	2004-06-04	2012-02-22	テバファーマシューティカルインダストリーズリミティド	イルベサルタンを含む医薬組成物
EP1685841A1 (fr)	2005-01-31	2006-08-02	Bayer Health Care Aktiengesellschaft	Prevention et traitement de troubles thromboemboliques
RU2441653C2 (ru) *	2005-05-31	2012-02-10	Милан Лэборетериз, Инк.	Композиции, содержащие небиволол
WO2007001066A1 (fr) *	2005-06-27	2007-01-04	Daiichi Sankyo Company, Limited	Préparation pharmaceutique contenant un antagoniste du récepteur de l'angiotensine ii et un bloqueur du canal calcique
DE102005045518A1 (de)	2005-09-23	2007-03-29	Bayer Healthcare Ag	2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
DE102005047561A1 (de)	2005-10-04	2007-04-05	Bayer Healthcare Ag	Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
AU2006299126B2 (en)	2005-10-04	2012-06-28	Bayer Intellectual Property Gmbh	Novel polymorphous form and the amorphous form of 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide
TWI399223B (zh) *	2006-09-15	2013-06-21	Daiichi Sankyo Co Ltd	奧美沙坦酯及氨氯地平之固體劑型
US20090076104A1 (en) *	2007-09-17	2009-03-19	Protia, Llc	Deuterium-enriched losartan
SG171751A1 (en) *	2008-11-19	2011-07-28	Merial Ltd	Compositions comprising an aryl pyrazole and/ or a formamidine methods and uses thereof
WO2018002673A1 (fr)	2016-07-01	2018-01-04	N4 Pharma Uk Limited	Nouvelles formulations d'antagonistes du récepteur de l'angiotensine ii
CN107617107A (zh) *	2017-09-18	2018-01-23	浙江大学	一种复方血管紧张素转换酶类抗瘢痕制剂
CN107648611A (zh) *	2017-09-18	2018-02-02	浙江大学	复方血管紧张素转换酶类抗瘢痕外用制剂
CN110075304B (zh) *	2019-05-29	2020-02-11	四川大学华西医院	一种治疗骨关节炎的药物组合物及其用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU210339B (en) *	1985-05-21	1995-03-28	Pfizer	Process for preparing thiazolidinediones and their pharmaceutical compositions haring hypoglycemic effect
DE3536687A1 (de) *	1985-10-15	1987-04-16	Hoechst Ag	Verfahren zur behandlung von atherosklerose, thrombose und der peripheren gefaesskrankheit
US5231080A (en)	1985-10-15	1993-07-27	Hoechst Aktiengesellschaft	Method for the treatment of atherosclerosis, thrombosis, and peripheral vessel disease
US5138069A (en) *	1986-07-11	1992-08-11	E. I. Du Pont De Nemours And Company	Angiotensin II receptor blocking imidazoles
MX15171A (es) *	1988-03-08	1993-05-01	Pfizer	Derivados de tiazolidinodiona hipoglicemicos
US5223522A (en) *	1988-03-08	1993-06-29	Pfizer Inc.	Thiazolidinedione hypoglycemic agents
CA2016467A1 (fr) *	1989-06-05	1990-12-05	Martin Eisman	Methode de traitement de l'atherosclerose des vaisseaux peripheriques a l'aide d'un inhibiteur de l'hmg coa reductase et (ou) d'un inhibiteur de la squalene synthetase
DE3925759A1 (de) *	1989-08-03	1991-02-07	Thera Patent Verwaltungs Gmbh	Verwendung von ace-inhibitoren fuer die atheroskleroseprophylaxe
US5061694A (en) *	1989-10-23	1991-10-29	E. R. Squibb & Sons, Inc.	Method for stabilizing or causing regression of atherosclerosis in coronary arteries employing an ace inhibitor
CA2026686A1 (fr)	1989-10-30	1991-05-01	Werner Tschollar	Methode de prevention de l'apparition du diabete de type 11 par l'emploi d'un inhibiteur de l'enzyme de conversion
GB2241890A (en)	1990-03-12	1991-09-18	Squibb & Sons Inc	Preventing onset of or treating protein catabolism using an ace inhibitor
US5196444A (en) *	1990-04-27	1993-03-23	Takeda Chemical Industries, Ltd.	1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5298497A (en)	1990-05-15	1994-03-29	E. R. Squibb & Sons, Inc.	Method for preventing onset of hypertension employing a cholesterol lowering drug
CA2061607C (fr) *	1991-02-21	1999-01-19	Hiroaki Yanagisawa	Derives 1-biphenylimidazole, leur preparation et leur utilisation therapeutique
US5616599A (en)	1991-02-21	1997-04-01	Sankyo Company, Limited	Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
US5668117A (en)	1991-02-22	1997-09-16	Shapiro; Howard K.	Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
WO1994001433A1 (fr) *	1992-07-13	1994-01-20	Japan Tobacco Inc.	Nouveau compose de thiazolidinedione et son utilisation
WO1994019347A1 (fr) *	1993-02-24	1994-09-01	Sankyo Company, Limited	Remede contre l'arteriosclerose
JPH0741423A (ja)	1993-02-24	1995-02-10	Sankyo Co Ltd	動脈硬化症治療剤
DE4318813A1 (de) *	1993-06-07	1994-12-08	Merck Patent Gmbh	Imidazopyridine
NO303782B1 (no) *	1994-03-23	1998-08-31	Sankyo Co	Tiazolidin- og oksazolidinderivater og farmas°ytiske preparater inneholdende slike, samt deres anvendelse til fremstilling av medikamenter
EP0754042A4 (fr) *	1994-03-29	2004-06-23	Merck & Co Inc	Traitement de l'atherosclerose
TW438587B (en)	1995-06-20	2001-06-07	Takeda Chemical Industries Ltd	A pharmaceutical composition for prophylaxis and treatment of diabetes
EP1192951A3 (fr)	1996-04-05	2004-04-21	Takeda Chemical Industries, Ltd.	Combinaison pharmaceutique comprenant un composé ayant une activité antagoniste de angiotensine II et un autre composé

1997
- 1997-07-11 CA CA002261040A patent/CA2261040C/fr not_active Expired - Lifetime
- 1997-07-11 RU RU2001126527/14A patent/RU2220723C2/ru active
- 1997-07-11 HU HU0600501A patent/HU227399B1/hu unknown
- 1997-07-11 CN CNB03136392XA patent/CN1221259C/zh not_active Expired - Lifetime
- 1997-07-11 KR KR1019997000222A patent/KR100540618B1/ko not_active Expired - Lifetime
- 1997-07-11 DE DE69734405T patent/DE69734405T2/de not_active Expired - Lifetime
- 1997-07-11 AT AT97930762T patent/ATE283704T1/de active
- 1997-07-11 RU RU99103215/14A patent/RU2183128C2/ru active
- 1997-07-11 IL IL12805997A patent/IL128059A/xx not_active IP Right Cessation
- 1997-07-11 CN CNB971979391A patent/CN1155409C/zh not_active Expired - Lifetime
- 1997-07-11 CZ CZ20080174A patent/CZ300089B6/cs not_active IP Right Cessation
- 1997-07-11 DK DK01124669T patent/DK1175902T3/da active
- 1997-07-11 HU HU9903166A patent/HU225415B1/hu unknown
- 1997-07-11 AT AT01124669T patent/ATE306921T1/de active
- 1997-07-11 EP EP97930762A patent/EP0930076B1/fr not_active Expired - Lifetime
- 1997-07-11 EP EP01124669A patent/EP1175902B1/fr not_active Expired - Lifetime
- 1997-07-11 NZ NZ333723A patent/NZ333723A/xx not_active IP Right Cessation
- 1997-07-11 ES ES01124669T patent/ES2250283T3/es not_active Expired - Lifetime
- 1997-07-11 DK DK97930762T patent/DK0930076T3/da active
- 1997-07-11 CZ CZ0010299A patent/CZ299162B6/cs not_active IP Right Cessation
- 1997-07-11 DE DE69731840T patent/DE69731840T2/de not_active Expired - Lifetime
- 1997-07-11 WO PCT/JP1997/002407 patent/WO1998002183A1/fr active IP Right Grant
- 1997-07-11 ES ES97930762T patent/ES2232873T3/es not_active Expired - Lifetime
- 1997-07-11 PT PT97930762T patent/PT930076E/pt unknown
- 1997-07-11 AU AU34595/97A patent/AU714618B2/en not_active Expired
1999
- 1999-01-14 NO NO19990166A patent/NO322314B1/no not_active IP Right Cessation
2001
- 2001-08-21 US US09/933,922 patent/US6610682B2/en not_active Expired - Lifetime
- 2001-10-04 IL IL145758A patent/IL145758A/en not_active IP Right Cessation
2005
- 2005-12-16 NO NO20056021A patent/NO334217B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
AU3459597A (en)	1998-02-09
CA2261040A1 (fr)	1998-01-22
HU0600501D0 (en)	2006-08-28
ES2232873T3 (es)	2005-06-01
IL128059A (en)	2003-12-10
NZ333723A (en)	2000-09-29
CZ300089B6 (cs)	2009-01-28
WO1998002183A1 (fr)	1998-01-22
CN1221259C (zh)	2005-10-05
EP1175902B1 (fr)	2005-10-19
EP0930076B1 (fr)	2004-12-01
US6610682B2 (en)	2003-08-26
HUP9903166A3 (en)	2003-09-29
ATE283704T1 (de)	2004-12-15
IL128059A0 (en)	1999-11-30
DE69731840D1 (de)	2005-01-05
HUP9903166A2 (hu)	2000-09-28
RU2220723C2 (ru)	2004-01-10
US20020013308A1 (en)	2002-01-31
CZ10299A3 (cs)	1999-06-16
CZ299162B6 (cs)	2008-05-07
AU714618B2 (en)	2000-01-06
HU227399B1 (en)	2011-05-30
IL145758A (en)	2006-06-11
NO990166L (no)	1999-03-15
NO990166D0 (no)	1999-01-14
EP0930076A4 (fr)	2001-10-04
CA2261040C (fr)	2009-01-20
NO334217B1 (no)	2014-01-13
DE69731840T2 (de)	2005-08-04
CN1230122A (zh)	1999-09-29
KR20000023757A (ko)	2000-04-25
EP0930076A1 (fr)	1999-07-21
ES2250283T3 (es)	2006-04-16
HU225415B1 (en)	2006-11-28
NO20056021L (no)	1999-03-15
RU2183128C2 (ru)	2002-06-10
DK1175902T3 (da)	2005-12-19
CN1155409C (zh)	2004-06-30
CN1476833A (zh)	2004-02-25
DK0930076T3 (da)	2005-01-31
PT930076E (pt)	2005-01-31
KR100540618B1 (ko)	2006-01-12
DE69734405T2 (de)	2006-08-03
HK1020260A1 (en)	2000-04-07
EP1175902A1 (fr)	2002-01-30
ATE306921T1 (de)	2005-11-15
DE69734405D1 (de)	2006-03-02
HUP0600501A3 (en)	2008-10-28

Publication	Publication Date	Title
NO322314B1 (no)	2006-09-11	Farmasoytisk preparat, sett som omfatter flere beholdere, samt anvendelse av troglitazon, pioglitazon og/eller BRL-49653 ved fremstilling av et medikament.
CA2328730C (fr)	2007-08-21	Traitement de l'hypertension iatrogene et liee au vieillissement et compositions pharmaceutiques utiles a cet effet
NO314065B1 (no)	2003-01-27	Farmasöytisk sammensetning omfattende en insulinsensitivitetsenhancer og etbiguanid ved behandling av diabetes
SI9520047A (en)	1997-06-30	Pharmaceutical preparations and medicaments for the prevention and treatment of endothelial dysfunction
US20070287685A1 (en)	2007-12-13	Medicinal composition containing FBPase inhibitor
JPH0296537A (ja)	1990-04-09	プロタミンの使用における有害作用の予防または減少用組成物
AU2001225625A1 (en)	2002-07-18	Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders
US6642262B2 (en)	2003-11-04	Riluzole and alpha-tocopherol combination
KR100895031B1 (ko)	2009-04-24	지질 농후 플라크의 감소, 안정화 및 파열 방지 방법
CA2551963C (fr)	2009-06-23	Compositions pharmaceutiques et traitement de l'arteriosclerose avec du cs-866
HK1020260B (en)	2005-05-06	Pharmaceutical compositions comprising cs-866 and insulin resistance improving agents and their use for the treatment of arteriosclerosis and xanthoma
JPH1081632A (ja)	1998-03-31	医薬
HK1040189B (en)	2005-12-30	Use of cs-866 (olmesartan) in the manufacture of a medicament for treating arteriosclerosis
JP2008094852A (ja)	2008-04-24	医薬
MXPA04001174A (es)	2005-02-17	Tratamiento para lipodistrofia.
ITTO960379A1 (it)	1997-11-08	Composizione farmaceutica per malattie cardiovascolari e renali.
HK1104477A (en)	2008-01-18	Medicinal composition containing fbpase inhibitor
HK1021508A (en)	2000-06-16	Pharmaceutical composition

Legal Events

Date	Code	Title	Description
2017-07-31	MK1K	Patent expired